Completed OBSERVATIONAL NCT05349201

CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)

CAR-T Cells - Real Life Study Of Care Pathway And Total Cost Of Care For Patients Under Car T-Cell Treatment Based On The PMSI French Database

Sponsor: Novartis Pharmaceuticals

Conditions Acute Lymphoblastic Leukemia (ALL) Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions KYMRIAH YESCARTA

Updated 4 times since 2022 Last updated: Jun 29, 2022 Started: Dec 9, 2020 Primary completion: May 28, 2021 Completion: May 28, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B-Cell Lymphoma (DLBCL) and is currently completed. Novartis Pharmaceuticals leads this study, which shows 4 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Sep 2022 — Jul 2024 [monthly]

Completed
May 2022 — Sep 2022 [monthly]

Completed

First recorded

Dec 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• East Hanover, United States